Jeremy R. Beitler, MD, MPH

Dr. Jeremy Beitler is a pulmonary intensivist and NIH-funded physician scientist with expertise in individualized management of acute respiratory failure and design/conduct of acute care clinical trials. Clinically, he cares for critically ill patients in the medical intensive care unit (MICU) at Bellevue Hospital. His NIH-funded research program focuses primarily on individualizing mechanical ventilatory support and adjunctive therapies for patients with acute respiratory failure and sepsis. He also serves as Director of the NYU Acute Respiratory Failure and Sepsis Precision Interventions to Raise Health Equity (ASPIRE) Trials Program, a national clinical trials coordinating center whose mission is to accelerate recovery from critical illness by leading equitable, high-impact clinical trials to improve public health.

Acute respiratory distress syndrome (ARDS) occurs in up to one-quarter of all critically ill adults receiving mechanical ventilation. Despite considerable advances in understanding of disease pathogenesis, ARDS remains associated with high risk of death—up to 45% mortality for severe disease. The most effective proven therapy for ARDS is to limit the degree of lung mechanical stress with each breath. Yet, how best to personalize ventilatory support to each individual patient’s unique risk of lung injury is unclear. Dr. Beitler’s research seeks to address this gap by advancing understanding of the interaction between pulmonary biomechanics and lung biology. He uses advanced techniques such as esophageal manometry, electrical impedance tomography, and quantitative ventilator waveform analysis to phenotype lung mechanics at bedside. These measures are paired with molecular biomarker signatures to identify patients at greatest risk of biophysical lung injury who may benefit from individually tailored interventions to mitigate risk of further lung injury and untoward clinical outcomes.

Dr. Beitler would like to express his gratitude to the many patients and families who have so kindly agreed to participate in clinical studies. He sincerely believes your essential support leads directly to improving survival and decreasing morbidity for patients suffering from acute respiratory failure, sepsis, and other critical illnesses.